Moderna and cytomx announce strategic research collaboration for mrna-based conditionally activated therapeutics

Collaboration will combine moderna's mrna technology with cytomx's probody® platform to generate and develop therapeutics for oncology and non-oncology conditions cytomx to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments cambridge, ma and south san francisco, ca / accesswire / january 5, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and cytomx therapeutics, inc. (nasdaq:ctmx), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational mrna-based conditionally activated therapies utilizing moderna's mrna technologies and cytomx's probody® therapeutic platform. the research collaboration will leverage core scientific advances at moderna and cytomx.
MRNA Ratings Summary
MRNA Quant Ranking